In patients with SLE, treatments using anti-CD19 CAR T cell therapy have shown rapid reductions in anti-double-stranded DNA antibodies, suggesting that CD19-positive plasmablasts and plasma cells are primary sources of these autoantibodies (98). Here, CD19 is linked to systemic lupus erythematosus.